Fundraising FoxAscenta Capital — Full Portfolio
18 tracked investments · listed companies and verified rows first
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Founder)inFred Manby(Founder)inChao Zhang(Executive Officer)inTabbert Teng(Executive Officer)Neil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)in
Co-investorsAbingworthCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+7 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)
Co-investorsLongitude CapitalSamsara BioCapitalF-Prime Capital
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & Chief Executive Officer)in
Co-investorsAtlas VentureLightspeed Venture PartnersRA CapitalBessemer Venture PartnersPfizer VenturesFinchley Healthcare Ventures+3 more
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Board seatLorence Kim· per SEC Form D
Co-investorsBain Capital Life SciencesOrbiMedSR One Capital ManagementLilly Asia VenturesT. Rowe PriceTCG Crossover+3 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)
Board seatLorence Kim· per SEC Form D
Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+9 more
46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.
Fintech
Tim Clark(Managing Director)
Co-investorsHurricane VenturesAndreessen HorowitzAvaana CapitalBoxGroupClaypond CapitalFirst Round Capital+7 more
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture PartnersLongitude Capital+9 more
.png)
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical Devices
Co-investorsFrazier Life SciencesWUTIF CapitalBiotechnology Value FundLightspeed Venture PartnersLongitude CapitalNextech Invest+1 more
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.
Biotech
Co-investorsFrazier Life SciencesOrbiMedRA CapitalWellington ManagementFrazier
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)in
Co-investorsBain CapitalDelos CapitalDigitalis VenturesNew Enterprise Associates (NEA)Bain Capital Life SciencesBain Capital Tech Opportunities+4 more
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)in
Co-investors5AM VenturesAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedViking Global+4 more
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersBayern KapitalBioMedPartnerscoparionFrazier Life SciencesFund++7 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Abata TherapeuticsSanti TherapeuticsAngitiaCardurion PharmaceuticalsLatigo
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.